- S&P Affirms Rating on Valeant Pharma (VRX) Amid Weak Q3 Report, Cut Outlook -> Read this!
Streetinsider.com's Hot Lunchtime Reads 11/8: (DEPO) (VRX) (VIPS) (PGNX)
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 01/20: (SWKS) (EMES) (CF) Higher; (PSTI) (AFMD) (BMY) Lower (more...)
- Pre-Open Stock Movers 01/19: (CSX) (OCLR) (NFLX) Higher; (AMDA) (DRYS) (RCII) Lower (more...)
- Stemline Therapeutics (STML) Prices 4.5M Shares at $10
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesRoth Capital, Standard & Poor's
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!